CelLBxHealth PLC Announces Preliminary Fourth Quarter 2025 Financial Results

Rhea-AI Summary

CelLBxHealth (OTCQX->Pink: ANPCF) announced preliminary unaudited FY2025 results and further cost rationalisation on 16 January 2026. The company expects FY2025 revenue of approximately £1.4m with Q4 revenue ~£0.4m; ~£0.2m of sales were deferred into Q1 2026. Cash at 31 Dec 2025 was £7.3m. The business is consolidating Guildford operations, reducing headcount, and expects annualised cost savings of £5.9m. Ordinary shares were voluntarily delisted from OTCQX (last trade 31 Dec 2025) and began trading on the Pink Limited Market on 2 Jan 2026. Management cites a qualified 2026/27 sales pipeline of £12.6m (risk-weighted £4.5m) that underpins revenue targets. Final audited FY2025 results remain subject to change.

Positive

• Cash balance of £7.3m at 31 Dec 2025
• Expected annualised cost savings of £5.9m
• Qualified 2026/27 sales pipeline of £12.6m (risk-weighted £4.5m)

Negative

• FY2025 revenue below prior expectation at £1.4m (vs expected £1.6m)
• Deferred sales of approximately £0.2m into Q1 2026
• Voluntary delisting from OTCQX and move to Pink may reduce US liquidity

Key Figures

Q4 2025 revenue: £0.4 million FY 2025 revenue: £1.4 million Biopharma revenue: £0.3 million +5 more

8 metrics

Q4 2025 revenue £0.4 million Preliminary unaudited fourth quarter 2025 revenue

FY 2025 revenue £1.4 million Preliminary unaudited full year 2025 revenue

Biopharma revenue £0.3 million Full year 2025 biopharma revenues

Product revenue £1.1 million Full year 2025 product revenues

Expected FY 2025 revenue £1.6 million Management’s prior full year 2025 revenue expectation

Deferred contracts £0.2 million Aggregate value of sales contracts deferred into Q1 2026

Cash balance £7.3 million Cash at 31 December 2025

Annualised cost savings £5.9 million Expected annualised savings from restructuring and rationalisation

Market Reality Check

Price: $0.0670 Vol: Volume 200,000 is 17.15x ...

high vol

$0.0670 Last Close

Volume Volume 200,000 is 17.15x the 20-day average of 11,660, indicating elevated trading activity. high

Technical Price at 0.0168 is trading below the 200-day MA of 0.19 and near the 52-week low.

Peers on Argus

The stock fell 14.72% while key peers were mostly flat: BIOQ, BMKDF, IMMVF at 0%...

The stock fell 14.72% while key peers were mostly flat: BIOQ, BMKDF, IMMVF at 0%, ANPCY down 1.47%, and IZOZF up 1.2%, pointing to a stock-specific reaction.

Historical Context

2 past events · Latest: Oct 16 (Negative)

Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Oct 16	Leadership change	Negative	-47.7%	Interim CEO appointment, new board advisor, and planned company rebrand.
Sep 12	Board changes	Negative	-59.3%	CEO and Finance Director stepping down after shareholder discussions.

Pattern Detected

Recent leadership and strategic announcements have coincided with sharp negative price reactions.

Recent Company History

Over the past few months, the company announced major leadership and branding changes. On Sep 12, 2025, board changes, including the CEO and Finance Director stepping down, preceded a -59.28% move. On Oct 16, 2025, appointment of an interim CEO, a senior board advisor, and rebranding to CelLBxHealth plc saw a -47.7% reaction. Today’s preliminary 2025 earnings update, highlighting a revenue shortfall, follows this period of restructuring and refocusing.

Market Pulse Summary

This announcement outlines preliminary 2025 results, including £1.4 million in revenue versus an exp...

Analysis

This announcement outlines preliminary 2025 results, including £1.4 million in revenue versus an expected £1.6 million, with about £0.2 million of contracts deferred into early 2026. Management highlights a cash balance of £7.3 million and anticipated annualised cost savings of £5.9 million from restructuring, facility consolidation, and delisting from OTCQX. Investors may track delivery against the qualified £12.6 million sales pipeline and upcoming 2026 reporting milestones to assess progress.

Key Terms

circulating tumour cell, unaudited financial information, otcqx market, pink limited market, +4 more

8 terms

circulating tumour cell medical

"a leader in circulating tumour cell (CTC) intelligence, with tests and services"

Circulating tumour cells are cancer cells that have broken away from a solid tumour and entered the bloodstream, like seeds carried from a tree by the wind. They matter to investors because tests that detect or count these cells can indicate whether a cancer is spreading, how well a treatment is working, and may support development or approval of therapies and diagnostics, affecting the commercial value of related medical products and companies.

unaudited financial information financial

"The preliminary unaudited financial information for the year ended 31 December 2025"

Unaudited financial information is company financial data that has been prepared by management but has not been independently checked by an external auditor. It is like a draft version of a company's financial report: useful for getting a quick look at performance and trends, but potentially subject to corrections or adjustments. Investors use it for timely insight, while recognizing it carries more uncertainty than audited figures when making decisions.

otcqx market financial

"has voluntarily delisted its ordinary shares from trading on the OTCQX Market"

The OTCQX Market is the top tier of the over-the-counter (OTC) marketplace where companies that don’t trade on major stock exchanges can still be bought and sold. It matters to investors because firms on OTCQX must meet higher disclosure and financial standards than lower OTC tiers, making them generally easier to research and somewhat safer to trade, but they still tend to have lower liquidity and less regulatory oversight than exchange-listed stocks — like a vetted secondary marketplace with trade-offs in ease and risk.

pink limited market financial

"the Company has transitioned to trading on the Pink Limited Market."

A pink limited market is a segment of the stock market where shares of smaller or newer companies are traded, often with fewer regulations and less oversight than larger markets. It matters to investors because these markets can offer opportunities for growth but also carry higher risks due to less transparency and stability, similar to a marketplace where products are less tested and might be more uncertain.

risk weighted pipeline financial

"sales pipeline of approximately £12.6 million (risk weighted pipeline of £4.5 million)"

A risk weighted pipeline is a company’s list of development projects (like drug candidates or product lines) where each item is scaled by its estimated chance of success and its potential financial payoff, producing a single “expected value” for the whole pipeline. Investors use it to translate a mix of uncertain projects into a clearer picture of likely future revenue and risk—think of it as adding up a set of bets where each bet’s odds and payoff determine the overall expected return.

annual general shareholders' meeting regulatory

"June 30, 2026: Annual general shareholders' meeting"

A yearly meeting where a company’s shareholders and board of directors come together to review performance, vote on key issues (such as electing directors and approving auditors), and ask questions of management. Think of it like a town-hall or annual check-in where owners can influence how the company is run; outcomes can affect governance, dividend decisions and long-term strategy, all of which can influence the value and risks of an investor’s holdings.

inside information regulatory

"is deemed by the Company to constitute inside information as stipulated"

Information not available to the public that, if known, would likely cause a company’s stock or bonds to rise or fall—for example, undisclosed earnings, deals, product results, or management plans. It matters because trading on that information gives an unfair advantage, can distort market prices, and is typically illegal or subject to strict rules, so investors watch for proper disclosure and compliance to protect fair, transparent markets.

eu market abuse regulation (596/2014) regulatory

"as stipulated under the EU Market Abuse Regulation (596/2014)"

An EU market abuse regulation is a set of rules that prevents cheating in financial markets by banning insider trading, misleading market manipulation, and requiring timely public disclosure of important company information. Think of it like a referee and scoreboard that make sure everyone plays by the same rules and sees the same key facts; that fairness helps prices reflect true value, protects ordinary investors, and creates legal obligations and penalties that can affect a company's stock and investor decisions.

AI-generated analysis. Not financial advice.

GUILDFORD, SURREY / ACCESS Newswire / January 16, 2026 / CelLBxHealth plc (AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, announces an update on 2025 unaudited financial results and further cost rationalisation as it looks to drive commercial progress in 2026.

Preliminary 2025 financial results

The Company now expects to report fourth quarter and full year 2025 revenues of approximately £0.4 million and £1.4 million respectively. The full year biopharma and product revenues were £0.3 million and £1.1 million respectively. The Company was expecting to achieve revenues of £1.6million for the year ended 31 December 2025, however a few sales contracts, with an aggregate value of approximately £0.2 million, were deferred into the first quarter of 2026.

Cash at 31 December 2025 was £7.3 million, providing a strong balance sheet from which to execute on the new strategy.

Cost rationalisation

The Company is reducing costs at all levels and consequently has voluntarily delisted its ordinary shares from trading on the OTCQX Market due to low trading volume and the associated administrative requirements. The Company's last day of trading on the OTCQX Market was 31 December 2025. Beginning 2 January 2026, the Company has transitioned to trading on the Pink Limited Market.

The Company is also rationalising its operations at Guildford into one facility. Along with headcount reductions and other restructuring activities, total cost savings are expected to be approximately £5.9 million on an annualised basis.

Outlook for 2026

Further to the fundraising announced in late November 2025, the Company is now pursuing its revised business strategy, focused on the delivery of commercial milestones from its qualified 2026/27 sales pipeline of approximately £12.6 million (risk weighted pipeline of £4.5 million), which underpins its revenue growth targets

2026 Reporting Calendar

• April 2026: Q1 2026 financial results and business update

• June 2026: preliminary FY2025 financial results

• June 30, 2026: Annual general shareholders' meeting

• July 2026: Q2 2026 financial results and business update

• November 2026: Q3 2026 financial results and business update

Financial information and auditor review

The preliminary unaudited financial information for the year ended 31 December 2025 set out above has been prepared from the Company's internal management accounts. The Company has not yet finalised its results for the year ended 31 December 2025. Accordingly, the final audited results may differ from the preliminary unaudited financial information presented above, and such differences may be material.

Peter Collins CEO of CelLBxHealth commented:

'The Company remains on track with the execution of its organisational restructure and delivery of associated cost-saving measures. With management focused on refining the Company's business strategy, securing funding and implementing the restructure during the fourth quarter of 2025, some sales contracts, with an aggregate value of approximately £0.2 million, were deferred into the first quarter of 2026.'

For further information:

CelLBxHealth plc Peter Collins, Chief Executive Officer	+44 (0) 1483 343434 investor@cellbxhealth.com
Cavendish (NOMAD and Broker) Geoff Nash / Isaac Hooper (Corporate Finance) Sunila de Silva (Corporate Broking) Nigel Birks (Life Science Specialist Sales)	+44 (0) 20 7220 0500
FTI Consulting Simon Conway, Ciara Martin, Sam Purewal	+44 (0) 203 727 1000

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

Notes for editors

About CelLBxHealth plc

CelLBxHealth plc is a precision CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.

Commercial activities centre on (1) Product Sales: Accelerating Parsortix platform adoption and consumable sales through CROs and clinical lab partnerships. (2) Laboratory services: Clinical trial support and assay development (3) Lab Developed Tests (LDTs): Strategic partnerships combined with a focused in-house development programme.

The product portfolio comprises the Parsortix® platform with associated consumables and assays. Laboratory services are delivered from CelLBxHealth's GCLP compliant UK laboratory, providing bespoke clinical-trial support and assay development.

For more information, visit https://cellbxhealth.com/.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Cellbxhealth PLC

View the original press release on ACCESS Newswire

FAQ

What were CelLBxHealth (ANPCF) preliminary FY2025 revenues and cash position?

Preliminary FY2025 revenue is ~£1.4m with cash of £7.3m at 31 Dec 2025.

Why did CelLBxHealth (ANPCF) move from OTCQX to the Pink market?

The company voluntarily delisted from OTCQX due to low trading volume and administrative requirements and transitioned to the Pink Limited Market on 2 Jan 2026.

How much annualised cost savings did CelLBxHealth (ANPCF) forecast from restructuring?

The company expects approximately £5.9m in annualised cost savings from consolidation, headcount reductions, and other restructuring.

How did deferred contracts affect CelLBxHealth (ANPCF) FY2025 revenue?

Approximately £0.2m of sales contracts were deferred into Q1 2026, reducing FY2025 revenue versus prior expectations.

What sales pipeline supports CelLBxHealth (ANPCF) 2026 revenue targets?

Management cites a qualified 2026/27 sales pipeline of £12.6m and a risk-weighted pipeline of £4.5m.

Are CelLBxHealth (ANPCF) FY2025 results final and audited?

No; the figures are preliminary unaudited management accounts and the final audited results may differ materially.